Indication intelligence, analysis and sector perception

Bellicum Pharmaceuticals (BLCM) closes 1.04 M share offering

November 4, 2020 8:21am

BLCM priced offering at $6.025 raising $25 million

Bellicum Pharmaceuticals (BLCM) closed its offering of 1,04 M shares, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock; priced at $6.025

H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

The Bottom Line: I am shocked the offering was completed as the stock decelerated, I thought it would re-priced, pulled and/or postponed (?) as the interim trial results of BPX-601 were "encouraging" in terms of safety and GoCAR-T cell activation, but clinically meaningful efficacy was not observed (the basis for the offering(?) and pricing is well-off the mark. BLCM slashed its workforce by 79% as part of a restructuring, following disappointing data from a trial of its pancreatic cancer treatment.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.